India, Nov. 4 -- Alamar Biosciences, Inc. (ALMR), a precision proteomics company focused on early disease detection, reported financial results for the third quarter ended September 30, 2026, and raised its full-year 2026 revenue guidance.
Alamar develops highly sensitive protein detection and analysis technologies through its proprietary NULISA platform and ARGO HT System, supporting research into disease biomarkers and precision medicine.
Third Quarter 2026 Results
Revenue increased 68% to $33.5 million from $19.9 million in the prior-year quarter.
Gross margin improved to 61.5% from 59.7% a year earlier, primarily reflecting lower instrument costs, higher average selling prices for consumables, improved service margins and a favorabl...